Article: NAD+ Deficiency Drives Kidney Dysfunction in Cockayne Syndrome: Preclinical Findings

PrevNext
Kidney Health Neurological Health Orphan Disease Preclinical

NAD+ Deficiency Drives Kidney Dysfunction in Cockayne Syndrome: Preclinical Findings

Synopsis

Cockayne Syndrome (CS) is a premature aging disorder caused by mutations in the CSA and CSB genes, leading to problems like early aging, nerve damage, and kidney dysfunction. Cells from CS patients show low levels of NAD+, a molecule essential for cell health and kidney function. This study found that CS mice have severe kidney damage and impaired NAD+ production. In human kidney cells, reducing CSA or CSB caused persistent activation of a gene regulator (ATF3) that blocks a key enzyme for making NAD+, leading to low NAD+ levels and disrupted kidney cell function.

Journal

Cell Death & Differentiation

Share

Read more

Amyotrophic Lateral Sclerosis (ALS)

NAD+ Augmentation as a Disease-Modifying Strategy for Neurodegeneration: Review

SynopsisNeurodegenerative diseases are a growing global health problem with no current treatments that slow or stop their progression. Boosting nicotinamide adenine dinucleotide (NAD+) has emerged ...

Read more
Clinical

Nicotinamide Riboside Supplementation Benefits in Werner's Syndrome: Clinical Findings

Objectives To evaluate the safety and efficacy of oral NR supplementation in patients with Werner Syndrome (WS). Journal Aging Cell Key Outcomes NR improved arterial stiffness, as measured by the...

Read more